2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Non-Biological Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bleeding and Clotting, Platelet Disorders, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3850 A new oral fixed-dose combination of decitabine/cedazuridine demonstrated equivalent exposure to parenteral formulation, with consistent efficacy and manageable safety profiles in Chinese patients with myelodysplastic syndromes

Xinping Zhou, Wei Yang2, Hu Zhou, MD3, Bing Li, MD4, Sujun Gao, MD5, Fei Li, MD, PhD6, Miao Miao7, Songfu Jiang8, Wei WANG, MD9, Yu Cao10, Zhichao Chen, MD11, Xiaoyu Zhu, MD12, Li Wang, MD13, Xin Du14, Yu Wu15, Rong Fu, MD16, Qingchi Liu17, Ling Jiang18, Aram Oganesian, PhD19, Harold Keer, MD, PhD20, Yoshitaka Kotobuki21, Masatoshi Ito22, Meiyu Wang23, Jie Jin24, Hongyan Tong, MD, PhD25
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 Shengjing Hospital of China Medical University, Shenyang, China
3 Henan Cancer Hospital, Zhengzhou, China
4 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 The First Hospital of Jilin University, Changchun, China
6 The First Affiliated Hospital of Nanchang University, Nanchang, China
7 The First Affiliated Hospital of Soochow University, Suzhou, China
8 The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
9 The Affiliated Hospital of Qingdao University, Qingdao, China
10 The Affiliated Hospital of Qingdao University, Qingdao, China
11 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12 The First Affiliated Hospital of USTC, Hefei, China
13 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
14 Guangdong Provincial People’s Hospital, Guangzhou, China
15 West China Hospital, Sichuan University, Chengdu, China
16 Tianjin Medical University General Hospital, Tianjin, China
17 The First Hospital of Hebei Medical University, Shijiazhuang, China
18 Nanfang Hospital, Southern Medical University, Guangzhou, China
19 Taiho Oncology, Inc., Pleasanton, United States
20 Taiho Oncology, Inc., Pleasanton, United States
21 Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
22 Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
23 Otsuka Beijing Research Institute, Beijing, China
24 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
25 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

Introduction

Hypomethylating agents (HMA) remain the standard of care for higher risk myelodysplastic syndromes (MDS). A fixed-dose combination (FDC) tablet containing decitabine (35 mg) and cedazuridine (100 mg; DEC-C) has been approved by Food and Drug Administration (FDA) and is recommended by National Comprehensive Cancer Network (NCCN) as an oral HMA option alongside parenteral formulations. Cedazuridine inhibits the first-pass elimination of decitabine by the enzyme cytidine deaminase, enabling oral administration of 35 mg decitabine to achieve exposure equivalent to that of intravenous (IV) infusion at 20 mg/m2. To extend this indication in Chinese patients, a new dosage regimen of decitabine (30 mg) and cedazuridine (100 mg; DEC-C) was developed via simulations incorporating Asian population characteristics using a semi-empirical population pharmacokinetics (popPK) model. This trial was aimed to evaluate the exposure equivalence, efficacy, and safety of this new oral FDC in patients with MDS in China.

Methods

This was an open-label, crossover, pharmacokinetic and efficacy bridging trial to evaluate DEC-C versus IV DEC in Chinese patients with MDS. Eligibility criteria included MDS at higher risk (International Prognostic Scoring System [IPSS] intermediate-1-risk and above) or chronic myelomonocytic leukemia (CMML). The trial was divided into two parts. Patients enrolled in part 1 were randomized 1:1 to two cohorts to receive DEC-C (one tablet/day on Day 1?5) or IV DEC (20 mg/m2/day on Day 1?5) in a crossover way during the first two cycles for exposure assessment. Starting from cycle 3 in part 1 and all cycles in part 2, patients received DEC-C on Day 1?5 in 28-day cycles, until disease progression, unacceptable toxicity or discontinuation determined by patients or investigators. All patients enrolled in part 1 and part 2 were reported in the efficacy response analyses in line with intention-to-treat (ITT) principle. The trial was registered on ClinicalTrials.gov (NCT06091267) and Chinadrugtrials.org.cn (CTR20233084).

Results

Between October 2023 and June 2025, 73 patients (part 1 and part 2; median age: 65 years [range: 33?82]; 43 [58.9%] male) were enrolled in 15 centers. 70 (95.9%) patients were diagnosed with MDS and 3 (4.1%) were CMML.

The geometric least squares mean ratio of area under curve during 5 days treatment (5day_AUC0-τ) between DEC-C and IV DEC in paired primary population from part 1 (n=21) was 93.33% (90%CI: 82.6%?105%), falling within the prespecified equivalence range, and was supported by popPK results indicating the selected dose 30/100 mg exhibited most equivalent exposure to IV DEC among all simulated decitabine doses (range: 25?35 mg).

By May 2026, after a median of 5 (range: 1?30) cycles of treatment, per International Working Group (IWG) 2006, the overall response rate (ORR) was 54.8% (40/73), with primary efficacy endpoint complete response (CR) rate of 21.9% (16/73, 95%CI: 13.08%?33.14%) which is consistent with historical data overseas, marrow complete response (mCR) with hematological improvement (HI) rate of 8.2% (6/73), mCR without HI rate of 16.4% (12/73), and HI only rate of 8.2% (6/73). Additionally, per IWG 2023, the ORR rate was 56.2% (41/73), with CR or equivalent rate of 20.5% (15/73), CR with limited count recovery (CRL) rate of 17.8% (13/73), CR with partial hematologic recovery (CRh) rate of 1.4% (1/73), and HI rate of 16.4% (12/73). After a median follow-up of 17 (range: 1?31) months, the median overall survival (OS) was not reached (NR) (95%CI: 19.0 months?NR), with 12-month and 24-month OS rates of 75.0% and 57.6%; and the median leukemia free survival (LFS) was 24.9 (95%CI: 15.7?NR) months, with 12-month and 24-month LFS rates of 69.2% and 52.8%.

No statistical significance in safety was observed between DEC-C and IV DEC in the first cycle in part 1 (each n=13). Overall, the proportion of treatment emergent adverse events with fatal outcome was 6.8% (5/73), of which 4.1% (3/73) were considered as treatment related (1.4% [1/73] each for pneumonia, sepsis, and septic shock).

Conclusions

We verified exposure equivalence, consistent efficacy, and manageable safety profiles of a new oral FDC of decitabine (30 mg) and cedazuridine (100mg), supporting its use as the first oral HMA option alongside parenteral formulations for patients with MDS in China.
Xinping Zhou: No relevant conflicts of interest to declare.